Neurocrine Biosciences Hosts Webcast Announcing Worldwide Collaboration With GlaxoSmithKline for CRF Receptor Antagonist
SAN DIEGO, July 24 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will be hosting a Webcast announcing a worldwide collaboration with GlaxoSmithKline for CRF Antagonists including the Phase I compound NBI-34041. The Webcast will be held July 24, 2001 at 11:00 AM Eastern Standard Time (EST)/ 8:00 AM Pacific Standard Time (PST). Participants may access the Webcast through a link provided via the Company's website at www.neurocrine.com.
Gary Lyons, President and CEO of Neurocrine Biosciences will discuss the collaboration. If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including anxiety, depression, irritable bowel syndrome, insomnia, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X33121615
SOURCE Neurocrine Biosciences
Web site: http: //www.neurocrine.com
CONTACT: Claudia Jones or Paul Hawran of Neurocrine Biosciences, +1-858-658-7600